Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ribupatide · 3 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| Ribupatide: Dose 1 | EXPERIMENTAL | Participants will receive Dose 1 of ribupatide once weekly. |
| Ribupatide: Dose 2 | EXPERIMENTAL | Participants will receive Dose 2 of ribupatide once weekly. |
| Ribupatide: Dose 3 | EXPERIMENTAL | Participants will receive Dose 3 of ribupatide once weekly. |
| Ribupatide: Dose 4 | EXPERIMENTAL | Participants will receive Dose 4 of ribupatide once weekly. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to ribupatide once weekly. |
| Semaglutide | ACTIVE_COMPARATOR | Participants will receive semaglutide once weekly. |
| Name | Type | Description |
|---|---|---|
| Ribupatide | DRUG | SC Injection |
| Placebo | DRUG | SC Injection |
| Semaglutide | DRUG | SC Injection |
Key Inclusion Criteria: * Diagnosis of type 2 diabetes mellitus (T2DM). * Receiving stable therapy for T2DM for 3 months prior to Screening. This includes diet and/or exercise alone or in combination with any oral medication for T2DM treatment except for DPP-4 inhibitors. Participants can be treatm...
Top 20 of 32 competitors
Ribupatide is an investigational small molecule being developed for obesity and obesity with diabetes. It is studied in adults with obesity or overweight, including those with weight-related comorbidities and those with diabetes. Ribupatide is administered once weekly and is currently in Phase 3 clinical development.
Ribupatide is being developed by Kailera Therapeutics, Inc., a biopharmaceutical company traded under the ticker KLRA. The company is conducting Phase 3 clinical trials to evaluate the drug's efficacy and safety in participants with obesity or overweight, with or without diabetes.
Ribupatide is in Phase 3 clinical development. It is an investigational drug, not yet approved by regulatory authorities. Kailera Therapeutics is currently recruiting participants for three Phase 3 trials studying the drug in obesity and obesity with diabetes populations.
Ribupatide is being studied in three Phase 3 trials: NCT07284875 (obesity or overweight without diabetes, 2340 participants), NCT07284901 (obesity or overweight with diabetes, 1156 participants), and NCT07284979 (obesity without diabetes, comparing Ribupatide to semaglutide and placebo, 1200 participants). All trials are recruiting.
One Phase 3 trial, NCT07284979, directly compares Ribupatide administered once weekly with semaglutide and placebo in participants living with obesity who do not have diabetes. This trial is recruiting and has an enrollment target of 1200 participants across the United States, Australia, Bulgaria, Poland, and the United Kingdom.
No, Ribupatide is not the same as semaglutide. Ribupatide is a separate investigational small molecule developed by Kailera Therapeutics, while semaglutide is a different, already marketed medication. A Phase 3 trial (NCT07284979) is comparing Ribupatide directly against semaglutide and placebo in people with obesity.